Is this the most undervalued FTSE stock?

This FTSE stock has been in the wars since the start of the pandemic, and it can’t seem to buck the trend. Could this be the index’s most undervalued stock?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE:SN) is a FTSE 100 stalwart. It currently has a market cap of £8.5bn and it’s one of the most respected medical device manufacturers around the world. However, things haven’t been going to plan for the company and its investors.

While a turnaround is on the corner, is it time we started seeing this hip replacement specialist as a slam dunk bargain?

Created with Highcharts 11.4.3Smith & Nephew Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Share price targets

When I’m looking to assess how much a company should be worth, I often find the best place to start is the share price targets. These are targets created by City and Wall Street analysts, and when compiled into a consensus opinion, they can be incredibly useful.

Should you invest £1,000 in Smith & Nephew Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Smith & Nephew Plc made the list?

See the 6 stocks

In the case of Smith & Nephew, we can see that the stock has no ‘Sell’ or ‘Underperform’ ratings. In fact, there are nine ‘Buy’ ratings, four ‘Outperform’ ratings and five ‘Hold’ ratings. That’s a very good sign.

But what’s an even stronger sign is the average share price target, which is currently £13.11. That’s a considerable 34.8% above the current share price. In the current market, I’d suggest we don’t often see stocks that analysts contend to be that undervalued.

Of course, there’s a few caveats here. Firstly, it’s a little lazy just to use other people’s analysis. But secondly, these ratings aren’t always updated that often. This is especially the case for less prominent companies. As such, ratings and share price targets can get outdated. It’s often good practice to discount those published more than three months ago.

Value improving

In February, the medical device giant reported fourth-quarter revenue of $1.46bn, marking a 6.4% increase on an underlying basis. For the year as a whole, the company surpassed expectations with underlying revenue up 7.2%. For 2024, Smith & Nephew remained positive, suggesting further revenue growth in the range of 5% to 6%.

For 2024, analysts are now anticipating the company will deliver earnings per share of 46p. That will rise to 60.3p in 2025, and 73.1p in 2026. That’s 16.7% growth over the medium term. As a result, Smith & Nephew is currently trading at 21 times forward earnings. This then drops to 16 times in 2025, and 13.2 times in 2026.

In turn, that’s a price-to-earnings-to-growth (PEG) ratio of 1.25. If the company didn’t pay a dividend, this PEG ratio would suggest the company is overvalued. But given the 3.4% dividend yield, it’s inconclusive.

P/ESmith & NephewJohnson & JohnsonMedtronic
20242114.316.2
20251613.815.4
202613.213.413.2

It’s always important to compare this data with peers in the same sector, and that’s what I’ve done above. As we can see, towards the end of the forecasting period, Smith & Nephew in trading in line with its peers. It’s also growing faster so could be in better shape.

The bottom line

The advent of effective weight loss drugs has certainly made some analysts wary. After all, obesity is a major reason people need joint replacements. And these drugs have compounded the negative impact of the pandemic on the business.

Nevertheless, I think the long-term picture is positive. There’s certainly enough catalysts in our ageing populations. It might not be the whoppingly undervalued stock that the average share price target suggests, but I certainly think it’s trading below fair value.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James Fox has positions in Smith & Nephew Plc. The Motley Fool UK has recommended Smith & Nephew Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Like buying £1 for 51p

This seems ridiculous, but we almost never see shares looking this cheap. Yet this recent ‘Best Buy Now’ has a price/book ratio of 0.51. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 51p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 8.5%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

More on Investing Articles

Investing Articles

4 REITs Fools own for passive income

REITs often have higher-than-average dividend yields compared to other stocks, making them a solid choice to consider for passive income…

Read more »

artificial intelligence investing algorithms
Investing Articles

Up 272% in just a year, is Palantir stock just getting started?

This writer recognises that Palantir has grown its business very well -- but does the stock price offer him an…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Up 50%? The Aston Martin share price forecast is mind-blowing! 

If analysts are right, the Aston Aston Martin share price could absolutely rocket in the year ahead. Harvey Jones says…

Read more »

Investing Articles

As the S&P 500 drops, here are 2 Stocks and Shares ISA holdings I’m watching

Our writer has different views on how President Trump's tariffs might affect these two US holdings in his Stocks and…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

£10,000 invested in Tesla stock at Christmas is now worth…

Tesla stock has been one of best-performing investments of the past decade. But things haven't gone to plan for investors…

Read more »

Investing Articles

Up 279% in 5 years, could Meta stock keep soaring?

Meta stock has more than tripled in five years. This writer sees lots to like about the business but also…

Read more »

Pink 3D image of the numbers '2025' growing in size
Investing Articles

25% total return in a year? Is now the perfect time to buy BP shares?

BP shares are on the front line of today's global economic and political uncertainty but analysts think they can still…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

With Cash ISA changes coming, could now be the time to consider buying shares?

Changes to the Cash ISA could lead to greater investment in the stock market. This could be a good thing…

Read more »